Key Highlights

  • Nano-X Imaging (NASDAQ:NNOX) traded at USD 0.34 intraday on November 13, 2026, up 6.56%, with a Market Value of about USD 26.8 million, near its 52-week low of USD 0.31.
  • On November 9, 2026 the board approved measures to cut annualised operating expenses by 25% to 30%, including workforce reductions, with full implementation by the end of the first quarter of 2027.
  • Preliminary third quarter Revenue was about USD 4.3 million to USD 4.4 million, up from USD 3.4 million, while cash and deposits fell to about USD 26.0 million from USD 60.0 million at the end of 2025.
  • The company has said its cash is not sufficient for its plans for at least a year, raising substantial doubt about its ability to continue as a going concern.

Restructuring Is the Latest Move

The most recent and important update from Nano-X Imaging is its restructuring plan. On November 9, 2026 the board approved cost reduction and efficiency measures aimed at lowering annualised operating expenses by 25% to 30%, including reductions in the global workforce, with full implementation expected by the end of the first quarter of 2027. The company repeated that recurring losses and negative Operating Cash Flow raise substantial doubt about its ability to continue as a going concern, and said it is considering steps to regain compliance with the Nasdaq minimum bid price. The shares rose 6.56% to USD 0.34 on November 13 on Volume of about 1.21 million shares, below the three-month average of about 2.62 million. The rebound is small compared with the decline from a 52-week high of USD 4.71, which reflects how heavily the market has discounted the company's prospects. A reverse split is a likely option if the price stays below USD 1.00.

Revenue Is Growing, but Slowly

Nano-X, based in Petah Tikva, Israel, operates a medical imaging platform that includes the Nanox ARC digital tomosynthesis system, artificial intelligence software that reviews routine scans, teleradiology services and health IT tools. Preliminary third quarter revenue of about USD 4.3 million to USD 4.4 million was up from USD 3.4 million a year earlier. Teleradiology contributed about USD 3.1 million, flat, imaging systems and OEM sales about USD 0.3 million, and AI and software about USD 1.0 million, mainly from a health IT Business it recently consolidated. In the second quarter revenue was USD 4.2 million and the net loss USD 55.5 million, which included a USD 40.7 million non-cash impairment. Recent commercial news includes a distribution agreement in Thailand for AI software, but the company stressed that hospital discussions there are preliminary. The core hardware business remains small relative to the Investment made in it. Growth in software sales is the clearest sign of progress so far.

Cash Is the Critical Constraint

Cash, cash equivalents and deposits fell to about USD 26.0 million at September 30, 2026 from USD 60.0 million at the end of 2025, a decline of about USD 34 million in nine months. Even with an additional USD 8.5 million raised after June, that pace explains the Going Concern warning. The planned cost cuts would extend the runway, but the company will likely need new funding, which at the current share price would be highly dilutive. Nano-X Imaging (NASDAQ:NNOX) must show that savings arrive quickly and that AI and software revenue keeps growing to restore confidence.

Where Things Stand

Nano-X Imaging traded at USD 0.34 on November 13, 2026 after approving cost cuts of 25% to 30% and repeating a going concern warning. Revenue is growing modestly, but cash fell to about USD 26.0 million. Watch final third quarter results, the pace of savings, financing and Nasdaq compliance steps.